Susquehanna International Group, LLP Immatics N.V. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.93 - $12.92 $1.41 Million - $1.67 Million	-129,300 Reduced 66.96%	63,800 $727,000
Q2 2024 Aug 15, 2024	BUY	$9.78 - $13.49 $175,062 - $241,471	17,900 Added 10.22%	193,100 $2.24 Million
Q1 2024 May 07, 2024	SELL	$10.23 - $12.94 $6,138 - $7,764	-600 Reduced 0.34%	175,200 $1.84 Million
Q4 2023 Feb 14, 2024	SELL	$7.36 - $10.89 $181,056 - $267,894	-24,600 Reduced 12.28%	175,800 $1.85 Million
Q3 2023 Nov 14, 2023	SELL	$11.01 - $12.62 $280,755 - $321,810	-25,500 Reduced 11.29%	200,400 $2.32 Million
Q2 2023 Aug 11, 2023	BUY	$5.92 - $12.72 $715,136 - $1.54 Million	120,800 Added 114.94%	225,900 $2.61 Million
Q1 2023 May 16, 2023	SELL	$6.74 - $9.44 $233,878 - $327,568	-34,700 Reduced 24.82%	105,100 $725,000
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $556,255 - $800,178	69,100 Added 97.74%	139,800 $1.22 Million
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $234,017 - $923,342	70,700 New	70,700 $707,000
Q4 2021 Feb 14, 2022	BUY	$10.81 - $14.38 $786,968 - $1.05 Million	72,800 New	72,800 $978,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.